Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
von Lewinski, D; Kockskämper, J; Rübertus, SU; Zhu, D; Schmitto, JD; Schöndube, FA; Hasenfuss, G; Pieske, B.
Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium.
Eur J Heart Fail. 2008; 10(12): 1172-1176.
Doi: 10.1016/j.ejheart.2008.09.014
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- von Lewinski Dirk
- Co-Autor*innen der Med Uni Graz
- Kockskämper Jens
- Pieske Burkert Mathias
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice. Indirect evidence from clinical trials demonstrates that chronic inhibition of the renin-angiotensin-system (RAS) significantly reduces the incidence of AF. Since mechanisms of this protective effect of RAS-blockade are poorly understood, we directly tested proarrhythmic effects of angiotensin II (Ang II) in human atrial myocardium. Methods: Isolated trabeculae from human atrial appendages (n = 80) were electrically stimulated. We assessed isometric force and incidence of arrhythmic extra contractions (AECs) with and without increasing concentrations of Ang II (1-1000 nmol/L) in the absence or presence of receptor-blockade by saralasin (non-specific ATR-antagonist), irbesartan (AT1R-antagonist) or PD123319 (AT2R-antagonist). Results: Twitch force and AECs concentration-dependently increased with Ang II. Effects became significant at concentrations > 1 nmol/L Ang II and were maximal at 1000 nmol/L (increase in twitch force to 157 +/- 14% and AECs from 0 to 80%) saralasin and irbesartan partially prevented the inotropic effect of 100 nmol/L Ang II (by 45 +/- 12% and 68 +/- 6%; p < 0.05), and completely prevented the occurrence of AECs. Conclusion: Ang II exerts direct pro-arrhythmic effects in human atrial myocardium. These effects are mediated by AT I-receptors and can be prevented by AT1R-blockade. This mechanism may contribute to the beneficial effects of RAS-blockade on AF in clinical trials. (C) 2008 Published by Elsevier B.V. on behalf of European Society of Cardiology.
- Find related publications in this database (using NLM MeSH Indexing)
- Angiotensin II - antagonists and inhibitors Angiotensin II - drug effects
- Angiotensin II Type 1 Receptor Blockers - therapeutic use
- Atrial Fibrillation - etiology Atrial Fibrillation - metabolism Atrial Fibrillation - physiopathology
- Cardiotonic Agents - therapeutic use
- Female -
- Heart - drug effects
- Heart Atria - drug effects
- Humans -
- Incidence -
- Isometric Contraction - drug effects
- Male -
- Muscle, Skeletal -
- Myocardium - metabolism
- Renin-Angiotensin System - drug effects
- Risk Factors -
- Find related publications in this database (Keywords)
- Atrial fibrillation
- Heart failure
- Angiotensin
- Remodelling